EA201100297A1 - Биотесты на белок polyq - Google Patents

Биотесты на белок polyq

Info

Publication number
EA201100297A1
EA201100297A1 EA201100297A EA201100297A EA201100297A1 EA 201100297 A1 EA201100297 A1 EA 201100297A1 EA 201100297 A EA201100297 A EA 201100297A EA 201100297 A EA201100297 A EA 201100297A EA 201100297 A1 EA201100297 A1 EA 201100297A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polyq
protein
biotests
disease
monitor
Prior art date
Application number
EA201100297A
Other languages
English (en)
Inventor
Паоло Паганетти
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201100297A1 publication Critical patent/EA201100297A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

В заявке описаны биотесты на мутантный белок polyQ, связанный с заболеванием, и их применение в качестве диагностических средств для мониторинга прогрессирования заболевания или для мониторинга эффективности лечения этого заболевания. В предпочтительном варианте осуществления настоящего изобретения белок polyQ является polyQ-хантингтином.
EA201100297A 2008-08-04 2009-08-03 Биотесты на белок polyq EA201100297A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161736 2008-08-04
PCT/EP2009/060013 WO2010015592A2 (en) 2008-08-04 2009-08-03 Bioassay for polyq protein

Publications (1)

Publication Number Publication Date
EA201100297A1 true EA201100297A1 (ru) 2011-10-31

Family

ID=40090177

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100297A EA201100297A1 (ru) 2008-08-04 2009-08-03 Биотесты на белок polyq

Country Status (11)

Country Link
US (1) US20110136146A1 (ru)
EP (1) EP2307888A2 (ru)
JP (1) JP2011530074A (ru)
KR (1) KR20110056499A (ru)
CN (1) CN102171573A (ru)
AU (1) AU2009279181A1 (ru)
BR (1) BRPI0917564A2 (ru)
CA (1) CA2732693A1 (ru)
EA (1) EA201100297A1 (ru)
MX (1) MX2011001383A (ru)
WO (1) WO2010015592A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8903488B2 (en) 2009-05-28 2014-12-02 Angiodynamics, Inc. System and method for synchronizing energy delivery to the cardiac rhythm
US9895189B2 (en) 2009-06-19 2018-02-20 Angiodynamics, Inc. Methods of sterilization and treating infection using irreversible electroporation
MA34263B1 (fr) 2010-04-30 2013-05-02 Novartis Ag Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)
US9700368B2 (en) 2010-10-13 2017-07-11 Angiodynamics, Inc. System and method for electrically ablating tissue of a patient
DK2694964T3 (da) * 2011-04-07 2019-10-07 Scripps Research Inst High-throughput-screening for forbindelser, der modulerer niveauer af cellulære makromolekyler
US20130203068A1 (en) * 2012-02-06 2013-08-08 Perkinelmer Biosignal, Inc. Dual-acceptor time-resolved-fret
EP3166966A1 (en) 2014-07-10 2017-05-17 Affiris AG Substances and methods for the use in prevention and/or treatment in huntington's disease
CN109069870B (zh) * 2016-02-24 2022-04-29 洛克菲勒大学 基于胚胎细胞的用于亨廷顿氏病的治疗候选物筛选***、模型及它们的应用
US10905492B2 (en) 2016-11-17 2021-02-02 Angiodynamics, Inc. Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode
EP3694536A4 (en) * 2017-10-12 2021-08-18 The Regents of The University of California CELL-BASED IMPFASSAY FOR THE HUNTINGTON AGGREGATION
EP4200616A1 (en) * 2020-08-24 2023-06-28 Wave Life Sciences Ltd. Immunoassays for detecting wild type huntingtin protein and methods of treatment employing such immunoassays

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087217A1 (en) * 2004-03-05 2005-09-22 The General Hospital Corporation Compositions and methods for modulating interaction between polypeptides

Also Published As

Publication number Publication date
US20110136146A1 (en) 2011-06-09
MX2011001383A (es) 2011-04-21
AU2009279181A1 (en) 2010-02-11
EP2307888A2 (en) 2011-04-13
CN102171573A (zh) 2011-08-31
WO2010015592A2 (en) 2010-02-11
WO2010015592A3 (en) 2010-04-22
JP2011530074A (ja) 2011-12-15
CA2732693A1 (en) 2010-02-11
BRPI0917564A2 (pt) 2015-11-17
KR20110056499A (ko) 2011-05-30

Similar Documents

Publication Publication Date Title
EA201100297A1 (ru) Биотесты на белок polyq
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA200900345A1 (ru) Замещенные ациланилиды и способы их применения
EA201370208A1 (ru) Формы рифаксимина и их применение
NO20075527L (no) Beta-2 adrenoceptor agonists for treating connective tissue diseases of the skin
UA94221C2 (en) Lipocalin protein
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
CR10868A (es) Derivados de dihidropiridina utiles como inhibidores de la proteina quinasa
BRPI0813212A2 (pt) Métodos de tratamento de doenças e distúrbios mediados por serotonina
EA201101520A1 (ru) Способы диагностики онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
EA201101117A1 (ru) Ингибиторы дпп-4 для лечения диабета у детей
WO2009026657A8 (en) Flavonoid ppar agonists
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
DK1863899T3 (da) Hudbehandlingspræparater
BRPI0906167A2 (pt) uso de inibidor de serina protease no tratamento de doenças de pele.
MY147247A (en) Organic compounds and their uses
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
GT200600409A (es) Uso de agomelatina para obtener medicamentos propuestos para el tratamiento de trastornos del sueño en el paciente deprimido.
EA201500403A1 (ru) Соединения, активирующие теломеразу, и способы их применения
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
MY155340A (en) Use of cathepsin c